Novartis to pay up to $620 million for Corthera
Novartis is to acquire the privately held US biopharmaceutical company Corthera for $120 million upfront and up to $500 million in development and commercialisation milestones.
Novartis is to acquire the privately held US biopharmaceutical company Corthera for $120 million upfront and up to $500 million in development and commercialisation milestones.